Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Arie Belldegrun, M.D.
Arie Belldegrun, M.D.

Specialty:

Urology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Surgical Director, Genitourinary Oncology, Kidney Cancer Program
Physician, Prostate Research and Treatment Program
Member, JCCC Tumor Immunology Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Surgical Oncology, National Institutes of Health, The Clinical Center, 1985 - 1988
Residency:
Urology, Brigham and Women's Hospital, 1982 - 1985
Surgery, Beilinson Hospital, 1980 - 1982
Urology and Renal Transplantation, Beilinson Hospital, 1979 - 1980
Fellowship:
Research, Weizmann Institute of Science, 1976 - 1979
Medical Degree:
M.D., Hebrew University Hadassah Medical School, 1974

Contact Information:

Phone:
(310) 794-7700 Information and referral
(310) 206-6909 Genitourinary Oncology referring physician
(310) 206-5930 Kidney Cancer Program information and referral
(310) 451-8751 Kidney Cancer Program referring physician
(310) 794-7704 Prostate Research and Treatment Program information and referral -- Nazy Zomorodian, N.P., Program Coordinator
(310) 206-0297 Prostate Research and Treatment Program information and referral -- Lynn Keil, R.N., Program Coordinator
(310) 794-7700 Prostate Research and Treatment Program referring physician
Email:

Practice Information:

Clinical Interest(s):
BPH Microwave Therapy
Bladder
Bladder Cancer
Cryosurgery
Endoscopic Surgery
Fistula
Gene Therapy
General Urology, Male
Hematuria
Incontinence
Kidney Cancer
Kidney Cancer Laparoscopy
Kidney General
Laparoscopic Surgery
Masses
Nerve Sparing Prostatectomy
Neurogenic Bladder
Nocturia
Oncology
Penile Cancer
Peyronie's Disease
Prostate Cancer
Prostate General
Prostate Nodules
Reconstructive
Testicular Cancer
Testicular Mass-Pain
Ureteral Obstruction
Urethral Diverticulum
Urethral Obstruction
Urethral/Bladder Stricture
Urinary Diversion
Urinary Obstruction Male

Scientific Interest(s):

Dr. Arie Belldegrun's research focuses on targeted specific therapy and immunotherapy of kidney and prostate cancers.

Belldegrun's laboratory reported on the cloning of a tissue specific and androgen responsive novel 620 bp PSA promoter sequence and upstream sequence. The enhanced gene expression of the resulting construct, combined with its tissue specificity and androgen responsiveness, provide the foundation for the development of tissue specific vectors for prostate cancer gene therapy.

Belldegrun's laboratory also has studied the feasibility of isolating functional dentrictic cells from the peripheral blood of renal cell carcinoma patients and has compared their transduction efficiency using various methods of transferring gene markers into dentritic cells.

Selected Cancer-Related Publications:

Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials. Clin Cancer Res. 2007; 13(2 Pt 2): 703s-708s.

Pantuck AJ, Belldegrun AS, Figlin RA. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin Cancer Res. 2007; 13(2 Pt 2): 693s-696s.

Lam JS, Breda A, Belldegrun AS, Figlin RA. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J Clin Oncol. 2006; 24(35): 5565-75.

Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006; 12(13): 4018-26.

Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y, Rao J, Li W, Chen D, Langford MP, Duggan C, Belldegrun AS, Dubinett SM. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol. 2006; 177(6): 3582-9.